Tumor necrosis factor receptor 1 signaling resistance in the female myocardium during ischemia

Circulation

Volumn 114, Issue SUPPL. 1, 2006, Pages

  Wang, Meijing ^a   Tsai, Ben M ^a   Crisostomo, Paul R ^a   Meldrum, Daniel R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Ischemia; Receptors; Sex

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR RECEPTOR 1; INTERLEUKIN 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR BINDING PROTEIN 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BINDING PROTEIN-1; SOCS3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENDER; HEART FUNCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HYPOTHESIS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SEX DIFFERENCE; SIGNAL PROCESSING; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; HEART; HEART MUSCLE; HEART MUSCLE CELL; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION;

ANIMALS; ENZYME ACTIVATION; FEMALE; HEART; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747176302     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.001164     Document Type: Article

References (25)

1. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-1587.
2. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation. 2005;111:863-870.
3. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998;274(p 2):R577-R595.
4. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, Entman ML. Resident cardiac mast cells degranulate and release preformed TNF-α, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98:699-710.
5. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
6. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
7. Oral H, Dorn GW 2nd, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:4836-4842.
8. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis factor α-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
9. Gurevitch J, Frolkis I, Yuhas Y, Lifschitz-Mercer B, Berger E, Paz Y, Matsa M, Kramer A, Mohr R. Anti-tumor necrosis factor-α improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol. 1997;30:1554-1561.
10. Sugano M, Tsuchida K, Makino N. Intramuscular gene transfer of soluble tumor necrosis factor-α receptor 1 activates vascular endothelial growth factor receptor and accelerates angiogenesis in a rat model of hindlimb ischemia. Circulation. 2004;109:797-802.
11. Ramani R, Mathier M, Wang P, Gibson G, Togel S, Dawson J, Bauer A, Alber S, Watkins SC, McTiernan CF, Feldman AM. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. Am J Physiol Heart Circ Physiol. 2004;287:H1369-H1377.
12. Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H, Sekikawa K, Seishima M. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-α. J Am Coll Cardiol. 2002;39:1229-1235.
13. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
14. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-α-induced cardiomyopathy. Circulation. 2004;109:1892-1897.
15. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
16. McFarlane SM, Jupp OJ, Cobban HJ, Hunter I, Anderson HM, Vandenabeele P, Nixon GF, MacEwan DJ. Stimulation of stress-activated but not mitogen-activated protein kinases by tumour necrosis factor receptor subtypes in airway smooth muscle. Biochem Pharmacol. 2001;61:749-759.
17. Jupp OJ, McFarlane SM, Anderson HM, Littlejohn AF, Mohamed AA, MacKay RH, Vandenabeele P, MacEwan DJ. Type II tumour necrosis factor-α receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochem J. 2001;359(pt 3):525-535.
18. Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, Su MS. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem. 1999;6:807-823.
19. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci U S A. 1999;96:3763-3768.
20. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G, Cohen P, Fiers W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 1996;15:1914-1923.
21. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 2004;22:503-529.
22. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4:551-556.
23. Bai L, Yu Z, Qian G, Qian P, Jiang J, Wang G, Bai C. SOCS3 was induced by hypoxia and suppressed STAT3 phosphorylation in pulmonary arterial smooth muscle cells. Respir Physiol Neurobiol. 2005;152:83-91.
24. Sudo K, Yamada Y, Moriwaki H, Saito K, Seishima M. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine. 2005;29:236-244.
25. Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med. 2005;11:892-898.